<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Over 300 individuals have received fetal liver transplants for a spectrum of disorders including <z:hpo ids='HP_0002721'>immunodeficiencies</z:hpo>, <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo>, <z:hpo ids='HP_0001909'>leukemia</z:hpo> and <z:e sem="disease" ids="C0019247" disease_type="Disease or Syndrome" abbrv="">genetic disorders</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>In some instances, the objective has been to reconstitute the immune system from fetal liver-derived lymphoid stem cells </plain></SENT>
<SENT sid="2" pm="."><plain>In <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> and <z:hpo ids='HP_0001909'>leukemia</z:hpo> two distinct approaches have been used: engraftment of fetal liver-derived hematopoietic stem cells or attempts to stimulate recovery of autologous hematopoiesis via factors produced by fetal liver </plain></SENT>
<SENT sid="3" pm="."><plain>In <z:e sem="disease" ids="C0019247" disease_type="Disease or Syndrome" abbrv="">genetic disorders</z:e>, partial engraftment of fetal liver-derived hematopoietic and hepatic cells has been investigated </plain></SENT>
<SENT sid="4" pm="."><plain>This report critically reviews data presented at a symposium on fetal liver transplantation in New-Delhi, 1-5 February 1986 </plain></SENT>
</text></document>